Latest KFF Health News Stories
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Pacientes experimentan con drogas recetadas para luchar contra la vejez
Aún no se han realizado ensayos clínicos rigurosos a gran escala para estudiar el proceso de envejecimiento. Así y todo, pacientes experimentan con drogas para detener el paso del tiempo.
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
Estadounidenses van a México a comprar insulina por un costo mucho más bajo
Millones cruzan la frontera para tratamientos y para comprar medicinas. La pregunta es si es una práctica legal. En Utah establecen turismo médico.
Americans Cross Border Into Mexico To Buy Insulin At A Fraction Of U.S. Cost
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
False Lead: Senator’s Offer To Help Patient Import Cheap Insulin Goes Nowhere
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Podcast: KHN’s ‘What The Health?’ New Year, New Health Proposals
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”
‘We’re Fighting For Our Lives’: Patients Protest Sky-High Insulin Prices
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life-or-death issue. Now a grass-roots movement is pushing for change.
Planes privados de Medicaid reciben millones, pero… ¿quién supervisa el negocio?
Las aseguradoras contratistas de Medicaid, que ofrecen servicios llamados de atención administrada, están en el banquillo: expertos cuestionan los servicios que ofrecen.
As Billions In Tax Dollars Flow To Private Medicaid Plans, Who’s Minding The Store?
Insurance companies profit from government contracts but are subject to little oversight of how they spend the money or care for patients. The expansion of Medicaid under the Affordable Care Act has only exacerbated the problem.
Feds Settle Huge Whistleblower Suit Over Medicare Advantage Fraud
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
El alto precio de la insulina lleva a que pacientes la racionen, a riesgo de muerte
El precio de la insulina en los Estados Unidos aumentó más del doble desde 2012. Eso pone a la hormona que salva vidas fuera del alcance de algunas personas con diabetes.
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
Medicaid Expansion Making Diabetes Meds More Accessible To Poor, Study Shows
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
Expansión de Medicaid facilita el acceso de los más pobres a drogas anti diabetes
El estudio revela que las recetas para drogas contra la diabetes aumentaron un 40% en los estados que expandieron Medicaid bajo ACA. También lo hicieron los diagnósticos.
Esperanza y cautela por una vacuna de bajo costo contra la diabetes tipo 1
La vacuna, conocida como BCG, se utiliza en varios países para prevenir la tuberculosis y durante mucho tiempo se ha sabido que también estimula el sistema inmunitario.
Retooled Vaccine Raises Hopes As A Lower-Cost Treatment For Type 1 Diabetes
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.
